期刊文献+

Effects of statins on the liver: clinical analysis of patients with ischemic stroke 被引量:2

Effects of statins on the liver: clinical analysis of patients with ischemic stroke
原文传递
导出
摘要 Background Statins are one of the most common agents prescribed for ischemic stroke patients, but their side effects on the liver are worrisome to both physicians and patients. This study aimed to analyze the features and related factors of the hepatic side effects of, statins in patients with ischemic troke.Methods Four hundred and eighty-one patients with ischemic stroke who had been treated with statins at our department from July 1, 2008 to June 30, 2009 were investigated retrospectively. Liver function, including alanine aminotransferase (ALT) and aspartate aminotransferase (AST), within 6 months after they began to use statins and related factors were analyzed.Results The incidence of mild ALT and AST elevation, less than three times the upper limit of normal, and the incidence of moderate elevation, ALT and AST levels 3-10 times the upper limit of normal, in ischemic stroke patients who had been treated with statins were 2.3% and 2.1%, respectively. These incidences were higher than in patients with common hyperlipidemia or coronary heart disease. The relatively high incidence was associated with older age (〉65 years) and chronic liver diseases, and was not related to the type of stroke, gender, and reduction of low-density lipoprotein. The levels of ALT and AST normalized after withdrawal of statins or lowering the dosage. None of the patients developed hepatic failure.Conclusions Asymptomatic elevation of ALT and AST after administration of statins is more likely to occur in ischemic stroke patients than in others, and the elevation is related to age and chronic liver diseases. However, statins are still safe for ischemic stroke patients. Background Statins are one of the most common agents prescribed for ischemic stroke patients, but their side effects on the liver are worrisome to both physicians and patients. This study aimed to analyze the features and related factors of the hepatic side effects of, statins in patients with ischemic troke.Methods Four hundred and eighty-one patients with ischemic stroke who had been treated with statins at our department from July 1, 2008 to June 30, 2009 were investigated retrospectively. Liver function, including alanine aminotransferase (ALT) and aspartate aminotransferase (AST), within 6 months after they began to use statins and related factors were analyzed.Results The incidence of mild ALT and AST elevation, less than three times the upper limit of normal, and the incidence of moderate elevation, ALT and AST levels 3-10 times the upper limit of normal, in ischemic stroke patients who had been treated with statins were 2.3% and 2.1%, respectively. These incidences were higher than in patients with common hyperlipidemia or coronary heart disease. The relatively high incidence was associated with older age (〉65 years) and chronic liver diseases, and was not related to the type of stroke, gender, and reduction of low-density lipoprotein. The levels of ALT and AST normalized after withdrawal of statins or lowering the dosage. None of the patients developed hepatic failure.Conclusions Asymptomatic elevation of ALT and AST after administration of statins is more likely to occur in ischemic stroke patients than in others, and the elevation is related to age and chronic liver diseases. However, statins are still safe for ischemic stroke patients.
出处 《Chinese Medical Journal》 SCIE CAS CSCD 2011年第6期897-900,共4页 中华医学杂志(英文版)
基金 This study was supported by the grants from Natural Science Foundation of Zhejiang Province (No. Y2090184) and the Project of Chinese Traditional Medicine of Zhejiang Province (No. 2006Y005).
关键词 STATINS liver function ischemic stroke alanine aminotransferase aspartate aminotransferase statins liver function ischemic stroke alanine aminotransferase aspartate aminotransferase
  • 相关文献

参考文献1

二级参考文献10

  • 1HerrickJ.Certainclinicalfeaturesofsuddenobstructionofthecoronaryarteries[].TransAmAssocPhysicians.1912
  • 2FusterV,FayadZA,BadimonJJ.Acutecoronarysyndromes:biology[].The Lancet.1999
  • 3TreasureC,KleinJ,WeintraubW ,etal.Beneficialeffectsofcholesterol loweringtherapyonthecoronaryendotheliuminpatientswithcoronaryarterydisease[].The New England Journal of Medicine.1995
  • 4.SInvestigatorsRandomisedtrialofcholesterolloweringin4444patientswithcoronaryheartdisease:theScandinavianSimvastatinSurvivalStudy(4S)[].The Lancet.1994
  • 5NatarajanR,ReddyMA.MaliketalSignalingmechanismsofnuclearfactor kappab mediatedactivationofinflammatorygenesby13 hydroperoxyoctadecadienoicacidinculturedvascularsmoothmusclecells[].Arteriosclerosis Thrombosis and Vascular Biology.2001
  • 6BlumA,GiladiM,WeinbergM,KaplanG ,etal.Highanti cytomegalovirus(CMV )IgGantibodytiterisassociatedwithcoronaryarterydiseaseandmaypredictpost coronaryballoonangioplastyrestenosis[].The American Journal of Cardiology.1998
  • 7StrokaDM,BadrichaniAZ,BachFH ,etal.OverexpressionofA1,anNF kappaB inducibleanti apoptoticbclgene,inhibitsendothelialcellactivation[].Blood.19991
  • 8InoueT,UchidaT,KamishiradoH ,etal.Clinicalsignificanceofantibodyagainstoxidizedlowdensitylipoproteininpatientswithatheroscleroticcoronaryarterydisease[].Journal of the American College of Cardiology.2001
  • 9MoukarbelGV,ArnaoutMS,AlamSE C.reactiveproteinisamarkerforacomplexculpritlesionanatomyinunstableangina[].Clinical Cardiology.2001
  • 10RidkerPM,RifaiN,BraunwaldE ,etal.Elevationoftumornecrosisfactor alphaandincreasedriskofrecurrentcoronaryeventsaftermyocardialinfarction[].Circulation.2000

共引文献21

同被引文献14

  • 1Scott M. Grundy,James I. Cleeman,C. Noel Bairey Merz,H. Bryan Brewer,Luther T. Clark,Donald B. Hunninghake,Richard C. Pasternak,Sidney C. Smith,Neil J. Stone.Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines[J]. Circulation: Journal of the American Heart Association . 2004 (2)
  • 2Sandra Lewis.Lipid-lowering therapy: who can benefit[J]. Vascular Health and Risk Management . 2011 (defa)
  • 3Vasilios G Athyros,Konstantinos Tziomalos,Thomas D Gossios,Theodora Griva,Panagiotis Anagnostis,Konstantinos Kargiotis,Efstathios D Pagourelias,Eleni Theocharidou,Asterios Karagiannis,Dimitri P Mikhailidis.Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis[J]. The Lancet . 2010 (9756)
  • 4Rossana M. Calderon,Luigi X. Cubeddu,Ronald B. Goldberg,Eugene R. Schiff.Statins in the Treatment of Dyslipidemia in the Presence of Elevated Liver Aminotransferase Levels: A Therapeutic Dilemma[J]. Mayo Clinic Proceedings . 2010 (4)
  • 5Tomotaka Dohi,Katsumi Miyauchi,Shinya Okazaki,Takayuki Yokoyama,Naotake Yanagisawa,Hiroshi Tamura,Takahiko Kojima,Ken Yokoyama,Takeshi Kurata,Hiroyuki Daida.Early intensive statin treatment for six months improves long-term clinical outcomes in patients with acute coronary syndrome (Extended-ESTABLISH trial): A follow-up study[J]. Atherosclerosis . 2009 (2)
  • 6Edward J. Mills,Beth Rachlis,Ping Wu,Philip J. Devereaux,Paul Arora,Dan Perri.Primary Prevention of Cardiovascular Mortality and Events With Statin Treatments[J]. Journal of the American College of Cardiology . 2008 (22)
  • 7Terry A. Jacobson.Comparative pharmacokinetic interaction profiles of pravastatin , simvastatin , and atorvastatin when coadministered with cytochromeP450 inhibitors[J]. The American Journal of Cardiology . 2004 (9)
  • 8Marc A. Pfeffer,Anthony Keech,Frank M. Sacks,Stuart M. Cobbe,Andrew Tonkin,Robert P. Byington,Barry R. Davis,Carola P. Friedman,Eugene Braunwald.Safety and Tolerability of Pravastatin in Long-Term Clinical Trials: Prospective Pravastatin Pooling (PPP) Project[J]. Circulation: Journal of the American Heart Association . 2002 (20)
  • 9DE Cohen,FA Anania,N Chalasani,National Lipid Association Statin Safety Task Force Liver Expert Panel.An assessment of statin safety by hepatologists. The American Journal of Cardiology . 2006
  • 10Koren Michael J,Feldman Theodore,Mendes Robert A.Impact of high-dose atorvastatin in coronary heart disease patients age 65 to 78 years. Clinical Cardiology . 2009

引证文献2

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部